secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-05-22T20:30:23+00:00
Accession:  0001493152-26-025037
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants
---------------------------------------------------------------------------

- Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.
- Each unit includes one ADS (or pre-funded warrant) plus Series H/I/J warrants exercisable at $3.74 per ADS.
- Warrants require shareholder approval; pre-funded warrants exercisable immediately.
- Net proceeds for working capital and general corporate purposes; Paulson Investment paid 2% cash fee plus 117,647 ADSs.
- Offering exempt from registration under Section 4(a)(2) and Regulation D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/0001493152-26-025037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer